Navigation Links
Xceed Molecular Names Fran Tuttle to Its Board of Trustees
Date:10/9/2007

WELLESLEY, Mass., Oct. 9 /PRNewswire/ -- Xceed Molecular Corporation, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced today that Fran Tuttle has been appointed to Xceed's board of directors. Ms. Tuttle is president and chief executive officer of HX Diagnostics, a California-based company focused on developing a point-of-care diagnostic for avian flu.

"Fran is the ideal complement to our board," said Xceed's President and CEO, David Deems. "She has more than 20 years of leadership in the diagnostics industry -- including significant experience with commercialization of novel technologies. Her knowledge, counsel, and close connections with thought leaders in the field will be invaluable to us as we continue to further develop our products and solutions for multiplexed gene-expression tests for clinical research today, and in vitro diagnostics tomorrow."

Prior to HX Diagnostics, Ms. Tuttle was president and chief executive officer of Protedyne Corporation (now part of LabCorp), which developed robotics for the molecular-diagnostic-testing industry. Previously, she was senior vice president of near patient testing at Bayer Diagnostics, one of the world's largest diagnostic companies. At Bayer, she was responsible for a worldwide business of $400 million. Before joining Bayer Diagnostics, she spent 20 years at Chiron Diagnostics (formerly Ciba Corning Diagnostics), a leader in molecular and immunodiagnostics. Ms. Tuttle began her career as a CPA at Peat, Marwick, Mitchell and Company (now KPMG). She holds a master's in business administration from Harvard Business School as well as bachelor's degrees in accounting from the University of North Carolina at Chapel Hill and German from Duke University.

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics and improve health outcomes by providing a cost-effective, automated system and services that facilitate the rapid translation of novel multiplexed genomic tests from research into routine clinical use. We designed our proprietary system to perform multiplexed molecular assays with superior accuracy, reproducibility, speed, and scalability at significantly lower cost than conventional array- or PCR-based systems. Our offerings include: the Ziplex(TM) System for automated gene-expression analysis, comprising an automated workstation, TipChip consumable arrays, and reagents (available in the US and Canada for research use only); Signature Chips -- pre-configured arrays focusing on a number of specific disease targets; and custom array services. Xceed's R&D and manufacturing operations are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit http://www.Xceedmolecular.com.


'/>"/>
SOURCE Xceed Molecular Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AIDS toll set to exceed Black Death
2. America’s Demand For Organic Foods Far Exceeds the Suppl
3. Mercury Levels In Canned Tuna Exceed Guidelines
4. Cholesterol in Stroke Patients Exceeds National Guidelines
5. Dengue Deaths in Cambodia This Year Exceed 2006 Toll
6. Molecular markers for early diagnosis of breast and ovarian cancer
7. Scientists Developed Map For Brain Molecular Communities
8. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
9. Molecular Flaw Detected in Aggressive Breast Cancers
10. Molecular Computer Developed To perform Calculations From Within Human Body
11. Lung cancer molecular profile discovered by researchers.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a ... hours a day, Quick Care provides patients with the option to request and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet ... against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... Boston, MA (PRWEB) , ... April 24, 2017 ... ... the cardiovascular health of individuals with HIV because it is not known to ... statins may have favorable effects to both lower cholesterol levels and dampen inflammation ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Urology, Uro/Gyn and Gynecology markets with innovative and ... joined the Company as Senior Vice President, Marketing ... Mr. Keswani will report directly to Darin ... organization is delighted that Ash has joined the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: